Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.
You may also be interested in...
Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access
Witnesses call for political pressure on FDA to approve the Duchenne drug; patients and advocates also urge general approval reciprocity with Europe and incentives for pediatric trials; agency was not invited to testify.
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
Exclusive license adds to AMAG's cash reserves and further validates the anemia drug's safety profile
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
Exclusive license adds to AMAG's cash reserves and further validates the anemia drug's safety profile